JP2024526090A5 - - Google Patents

Info

Publication number
JP2024526090A5
JP2024526090A5 JP2023577355A JP2023577355A JP2024526090A5 JP 2024526090 A5 JP2024526090 A5 JP 2024526090A5 JP 2023577355 A JP2023577355 A JP 2023577355A JP 2023577355 A JP2023577355 A JP 2023577355A JP 2024526090 A5 JP2024526090 A5 JP 2024526090A5
Authority
JP
Japan
Prior art keywords
cells
manipulated
immune cells
domain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/033598 external-priority patent/WO2022266203A1/en
Publication of JP2024526090A publication Critical patent/JP2024526090A/ja
Publication of JP2024526090A5 publication Critical patent/JP2024526090A5/ja
Pending legal-status Critical Current

Links

JP2023577355A 2021-06-15 2022-06-15 同種ｃａｒ ｔ細胞の持続性を延長するための宿主ｃｄ７０＋アロ反応性細胞の選択的標的化 Pending JP2024526090A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163210979P 2021-06-15 2021-06-15
US63/210,979 2021-06-15
US202263351223P 2022-06-10 2022-06-10
US63/351,223 2022-06-10
PCT/US2022/033598 WO2022266203A1 (en) 2021-06-15 2022-06-15 Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence

Publications (2)

Publication Number Publication Date
JP2024526090A JP2024526090A (ja) 2024-07-17
JP2024526090A5 true JP2024526090A5 (https=) 2025-11-17

Family

ID=82608367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577355A Pending JP2024526090A (ja) 2021-06-15 2022-06-15 同種ｃａｒ ｔ細胞の持続性を延長するための宿主ｃｄ７０＋アロ反応性細胞の選択的標的化

Country Status (10)

Country Link
US (4) US20220409665A1 (https=)
EP (1) EP4355358A1 (https=)
JP (1) JP2024526090A (https=)
KR (1) KR20240021826A (https=)
AU (1) AU2022292640A1 (https=)
BR (1) BR112023026249A2 (https=)
CA (1) CA3221957A1 (https=)
IL (1) IL308468A (https=)
MX (1) MX2023014866A (https=)
WO (1) WO2022266203A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2025096594A2 (en) * 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
WO2019099479A1 (en) * 2017-11-14 2019-05-23 Memorial Sloan-Kettering Cancer Center Il-33 secreting immunoresponsive cells and uses thereof
CN112020518A (zh) * 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
EP4031150A4 (en) * 2019-09-16 2023-11-01 The General Hospital Corporation CD70-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF
WO2022129216A1 (en) * 2020-12-15 2022-06-23 Universiteit Antwerpen Cell-based therapeutics targeting cd70

Similar Documents

Publication Publication Date Title
Yan et al. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
Kershaw et al. Gene-engineered T cells for cancer therapy
Morgan et al. Engineering CAR-T cells for improved function against solid tumors
CN108276493B (zh) 一种嵌合抗原受体及其应用
CN107109421B (zh) Car表达载体及car表达t细胞
Jain et al. Concise review: emerging principles from the clinical application of chimeric antigen receptor T cell therapies for B cell malignancies
JP2020517259A5 (https=)
CN112979820B (zh) 靶向cd123的嵌合抗原受体及含有靶向cd123嵌合抗原受体的双靶点嵌合抗原受体
CA3045508A1 (en) Methods for modulation of car-t cells
Chu et al. Versatile CAR T-cells for cancer immunotherapy
JP2024526090A5 (https=)
US20240181056A1 (en) Chimeric antigen receptor (car)-t cells
King et al. Advances in tumour immunotherapy
CN117004604A (zh) 一种ciita基因被敲除的工程化免疫细胞及其用途
WO2022033483A1 (zh) 多功能的免疫效应细胞及其应用
CN116239692B (zh) 分离的抗体、包含该抗体的car及其用途
Zhang et al. Natural killer cell-based immunotherapies for colorectal cancer: Current strategies, challenges, and future perspectives
RU2024100696A (ru) Селективное нацеливание на cd70+ аллореактивные клетки хозяина для продления персистенции аллогенных т-клеток с car
AU2022262282A9 (en) Chimeric antigen receptor (car)-t cells
EP4372089A1 (en) Chimeric antigen receptor, cell capable of expressing said receptor, pharmaceutical composition containing said cell, method for producing said cell, and polynucleotide or vector which contains nucleotide sequence encoding said chimeric antigen receptor
Kudo et al. Specific targeting immunotherapy of cancer with bispecific antibodies
US20240207313A1 (en) Chimeric antigen receptor (car)-t cells
Schneider et al. T-Cell Immunotherapy: From Synthetic Biology to Clinical Practice
HK40093010A (zh) 涉及car工程化t细胞和细小病毒h-1的癌症疗法
EP4052716A1 (en) Cancer therapy involving car-engineered t-cells and parvovirus h-1